Virbac (XPAR:VIRP) FFO


XPAR:VIRP Virbac SA XPAR:VIRP
95 GF Score
Price €320.50
GF Value €365.68
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Virbac FFO?

FFO (Funds from operations) only applies to REITs.

XPAR:VIRP
95GF Score
Virbac SA XPAR:VIRP
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Virbac (XPAR:VIRP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €320.50 is trading 12.4% below its estimated GF Value™ of €365.68. GuruFocus considers Virbac to be Modestly Undervalued.

Key valuation signals for XPAR:VIRP:

  • FFO:
  • GF Value™: €365.68 vs. price of €320.50 (12.4% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the XPAR:VIRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Virbac Business Description

Other Exchanges VRBCF:USA0NM7:UKV16:Germany
Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score

Get the complete analysis for XPAR:VIRP

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€320.50
Price
€365.68
GF Value